Literature DB >> 12045386

Carvedilol: a nonselective beta blocking agent with antioxidant properties.

Wendy M Book1.   

Abstract

Despite advances in therapy, congestive heart failure is a major public health problem with a high mortality and morbidity. The benefits of beta blockers in slowing disease progression and decreasing mortality have recently been shown in large clinical trials. Oxidative stress contributes to disease progression in both post-myocardial reperfusion injury and dilated cardiomyopathy. Several medications are known to have antioxidant effects, including some angiotensin-converting enzyme inhibitors. Carvedilol is a non-selective beta blocker with antioxidant properties approved for use in congestive heart failure. Copyright 2002 CHF, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045386     DOI: 10.1111/j.1527-5299.2002.00718.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  10 in total

1.  Protective effect of carvedilol on abnormality of L-type calcium current induced by oxygen free radical in cardiomyocytes.

Authors:  Nian Liu; Ronghui Yu; Yanfei Ruan; Qiang Zhou; Jun Pu; Yang Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

2.  The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies.

Authors:  Zoltán Nádházi; Csaba András Dézsi
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

3.  Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats.

Authors:  Hesong Zeng; Xiaochun Liu; Huayue Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

4.  Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats.

Authors:  Vanessa Grandinetti; Fernando Pereira Carlos; Ednei Luiz Antonio; Helenita Antonia de Oliveira; Luis Felipe Neves Dos Santos; Amanda Yoshizaki; Barbara Sampaio Dias Martins Mansano; Flávio André Silva; Leslie Andrews Porte; Gianna Móes Albuquerque-Pontes; Paulo de Tarso Camillo de Carvalho; Martha Trindade Manchini; Ernesto Cesar Leal-Junior; Paulo José Ferreira Tucci; Andrey Jorge Serra
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

5.  Hepatoprotective Role of Carvedilol against Ischemic Hepatitis Associated with Acute Heart Failure via Targeting miRNA-17 and Mitochondrial Dynamics-Related Proteins: An In Vivo and In Silico Study.

Authors:  Doaa I Mohamed; Samar F Ezzat; Wael M Elayat; Omnyah A El-Kharashi; Hanaa F Abd El-Kareem; Hebatallah H Abo Nahas; Basel A Abdel-Wahab; Samar Zuhair Alshawwa; Asmaa Saleh; Yosra A Helmy; Eman Khairy; Essa M Saied
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-05

6.  Human cardiac tissue in a microperfusion chamber simulating extracorporeal circulation--ischemia and apoptosis studies.

Authors:  Engin Usta; Mirijam Renovanz; Migdat Mustafi; Gerhard Ziemer; Hermann Aebert
Journal:  J Cardiothorac Surg       Date:  2010-01-18       Impact factor: 1.637

7.  Cytoprotective Potential of Aged Garlic Extract (AGE) and Its Active Constituent, S-allyl-l-cysteine, in Presence of Carvedilol during Isoproterenol-Induced Myocardial Disturbance and Metabolic Derangements in Rats.

Authors:  Syed Mohammed Basheeruddin Asdaq; Obulesu Challa; Abdulhakeem S Alamri; Walaa F Alsanie; Majid Alhomrani; Abdulrahman Hadi Almutiri; Majed Sadun Alshammari
Journal:  Molecules       Date:  2021-05-27       Impact factor: 4.411

Review 8.  Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology.

Authors:  Alessia Arcaro; Flora Pirozzi; Annalisa Angelini; Cristina Chimenti; Lia Crotti; Carla Giordano; Daniele Mancardi; Daniele Torella; Carlo G Tocchetti
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

9.  Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats-A Comparison with Mesna.

Authors:  Anna Merwid-Ląd; Piotr Ziółkowski; Marta Szandruk-Bender; Agnieszka Matuszewska; Adam Szeląg; Małgorzata Trocha
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-29

Review 10.  Heart Failure and Drug Therapies: A Metabolic Review.

Authors:  Frank Yu; Bianca McLean; Mitesh Badiwala; Filio Billia
Journal:  Int J Mol Sci       Date:  2022-03-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.